NCT05304962View on ClinicalTrials.gov

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 4, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

September 30, 2026

Conditions
Breast Cancer
Interventions
DRUG

RGT-419B

oral capsules

DRUG

RGT-419B in combination with hormonal therapy

RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)

Trial Locations (8)

11776

RECRUITING

New York Cancer and Blood Specialists, Port Jefferson Station

30322

RECRUITING

Emory University, Atlanta

33612

RECRUITING

Moffitt Cancer Center, Tampa

34952

ACTIVE_NOT_RECRUITING

Hem-Onc Associates of the Treasure Coast, Port Saint Lucie

63110

RECRUITING

Washington University School of Medicine, St Louis

90404

RECRUITING

University California, Los Angeles, Los Angeles

92037

RECRUITING

University of California, San Diego, La Jolla

02142

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Regor Pharmaceuticals Inc.

INDUSTRY